Fig. 2: Effects of metreleptin in monogenic forms of lipodystrophy.
From: Genotype-stratified treatment for monogenic insulin resistance: a systematic review
Least square mean change in (a) Hemoglobin A1c (A1c), (b) Log10 serum triglyceride concentration and (c) Body Mass Index (BMI) in patients with partial lipodystrophy, generalized lipodystrophy, all forms of lipodystrophy, and subgroups with PPARG, LMNA, BSCL2, and AGPAT2 mutations. Error bars represent 95% confidence intervals. N = 64, 38, 102, 12, 52, 17, and 20 for change in A1c in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, PPARG, LMNA, BSCL2, and AGPAT2-associated lipodystrophy, respectively. N = 66, 40, 106, 12, 54, 19, and 20 for change in log10 triglycerides in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, PPARG, LMNA, BSCL2, and AGPAT2-associated lipodystrophy, respectively. N = 47, 14, 61, 10, 35, 8, and 7 for change in BMI in partial lipodystrophy, generalized lipodystrophy, all lipodystrophy, PPARG, LMNA, BSCL2, and AGPAT2-associated lipodystrophy, respectively.
